2Xideas AG Has $44.30 Million Holdings in IQVIA Holdings Inc. (NYSE:IQV)

2Xideas AG grew its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 14.5% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 225,423 shares of the medical research company’s stock after acquiring an additional 28,624 shares during the period. IQVIA comprises 5.9% of 2Xideas AG’s portfolio, making the stock its 4th biggest holding. 2Xideas AG’s holdings in IQVIA were worth $44,298,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of IQV. Vanguard Group Inc. boosted its holdings in IQVIA by 0.5% in the 4th quarter. Vanguard Group Inc. now owns 20,131,734 shares of the medical research company’s stock valued at $3,956,087,000 after purchasing an additional 105,504 shares during the period. Geode Capital Management LLC grew its position in IQVIA by 1.9% during the fourth quarter. Geode Capital Management LLC now owns 4,175,524 shares of the medical research company’s stock worth $818,315,000 after buying an additional 77,981 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in IQVIA by 2.5% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,438,726 shares of the medical research company’s stock worth $481,380,000 after acquiring an additional 59,426 shares during the last quarter. Cantillon Capital Management LLC boosted its position in shares of IQVIA by 12.3% during the 4th quarter. Cantillon Capital Management LLC now owns 2,066,144 shares of the medical research company’s stock valued at $406,018,000 after acquiring an additional 226,017 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in shares of IQVIA by 46.2% during the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after purchasing an additional 583,396 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors.

IQVIA Stock Performance

IQVIA stock opened at $154.63 on Friday. The stock’s 50 day moving average is $189.67 and its 200 day moving average is $203.82. The company has a market capitalization of $27.26 billion, a P/E ratio of 20.62, a PEG ratio of 1.99 and a beta of 1.46. IQVIA Holdings Inc. has a twelve month low of $154.35 and a twelve month high of $252.88. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, equities research analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have issued reports on IQV. Bank of America dropped their target price on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a research report on Friday, December 13th. Morgan Stanley upped their target price on shares of IQVIA from $245.00 to $250.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 11th. StockNews.com downgraded IQVIA from a “buy” rating to a “hold” rating in a research report on Wednesday, March 12th. Stifel Nicolaus cut their price objective on IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a report on Friday, February 7th. Finally, UBS Group decreased their price objective on IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a report on Friday, February 7th. Five analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $249.05.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.